Blog

Nue Life Health, a leading mental wellness company supporting patients undergoing psychedelic therapies, announced today the completion of a $1.9m financing by existing investors to support its next phase of evolution. In this next phase Nue Life will make its revolutionary “Nue app” and its “Nue score” available for free to any patient undergoing ketamine therapy. Since its inception, Nue Life focus has been delivering safe and effective “at-home” ketamine therapy to over eight thousand patients across the U.S., as evidenced by the recently published peer-reviewed study titled “Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label,…

Clearmind Medicine Inc. (Nasdaq, CSE: CMND / FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of the Company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind’s and SciSparc’s combination treatment for obesity and metabolic syndrome. Professor Joseph (Yossi) Tam, D.M.D., Ph.D., the Head of…

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the following investor conferences: A live audio webcast of the HC Wainwright presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days following the event. For more information, please visit ir.compasspathways.com. About COMPASS Pathways COMPASS Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving…

Numinus Wellness Inc., (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based investigational psychedelic-assisted therapies, announced a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS), to support psychedelic experiential opportunities for practitioners as part of a clinical study. If the Clinical Trial Application (CTA) submitted to Health Canada is approved, the MDMA-assisted therapy experiential opportunity would be available only through Numinus.  The CTA has been submitted by Numinus through its wholly-owned subsidiary Numinus Wellness Research Inc. If approved by Health Canada, the clinical trial would enable practitioners interested in MDMA-assisted therapy the ability to…

 Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Methylenedioxymethamphetamine (“MDMA”) and natural psilocybin, along with natural health product formulations, is pleased to announce that it has been selected to manufacture and supply MDMA for a practitioner experiential clinical trial, sponsored by Numinus Wellness Inc. (“Numinus”), announced earlier today. This clinical trial will provide practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training – through a…